IMMUNOTHERAPY FOR STAGE III NSCLC INCLUDED IN THE
Subsidy Coverage of
the CCF Medical Assistance
Programme
the CCF Medical Assistance
Programme
MEDICAL ASSISTANCE PROGRAMME FOR
Stage III Lung Cancer Patients on
Concurrent Chemotherapy and Radiation Therapy
Concurrent Chemotherapy and Radiation Therapy
IMMUNOTHERAPY FOR STAGE III NSCLC INCLUDED IN THE
Subsidy Coverage of
the CCF Medical Assistance
Programme
the CCF Medical Assistance
Programme
MEDICAL ASSISTANCE PROGRAMME FOR
Stage III Lung Cancer Patients on
Concurrent Chemotherapy and Radiation Therapy
Concurrent Chemotherapy and Radiation Therapy
|
Cancer
Immunotherapy Cancer immunotherapy is one of the most important medical advances of our time. It is the use of our own body's immune system to help fight cancer.1 This can be done in a couple of ways, such as stimulating our immune system to work harder or smarter...... |
Understanding
immunotherapy To better understand how immunotherapy works, it can help to know a little more about the immune system and cancer. However, do keep in mind that even the “basics” of immunotherapy can be complicated and confusing. If you have any questions...... |
|
What is the immune system?
|
How does the immune system work?
|
What is the role of the immune system in cancer?
|
How do cancer cells grow despite immune responses?
More about immunotherapy
| How immunotherapy works? |
| How is immunotherapy different from conventional cancer treatment? |
| How long will immunotherapy take to work? |
| Common side effects of immunotherapy and their management |
Immunotherapy for lung cancer
There have been many exciting advances in the field of lung cancer treatment. Until the mid-2000's, treatment options for lung cancer were mostly limited to surgery, chemotherapy and radiotherapy. Nowadays, patients with lung cancer often have newer treatment options. This section is to help you understand advances in the treatment of lung cancer using immunotherapies that boost your body's immune system to fight cancer.
| Understanding lung cancer |
| Immunotherapy for advanced non-small cell lung cancer (NSCLC) |
Immunotherapy for bladder cancer
Bladder cancer was the first indication for which an immunotherapy was granted approval in 1990.33 Since 2016, more immunotherapies have been approved, including several checkpoint inhibitors in both the first and second line settings. This page features information on bladder cancer and immunotherapy for people with bladder cancer.
| Understanding bladder cancer |
| Immunotherapy for locally advanced or metastatic bladder cancer |
Resources
|
Useful materials
|
Patient FAQs pamphlet
|
Other materials
|
Useful Link
